Imaging Frequency for Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas

Risk Stratification and Imaging Intervals

• Patients with main duct IPMN (MD-IPMN) or mixed-type IPMN who are fit for surgery should undergo resection due to high malignancy risk (56-91%) 1, 4
• After resection of MD-IPMN or mixed-type IPMN with high-grade dysplasia, follow-up should occur every 6 months for the first 2 years, then yearly thereafter 5
• For Branch Duct IPMNs (BD-IPMNs) without high-risk features, initial follow-up at 6 months, and if stable, imaging every 6-12 months for the first 2 years 6
• For BD-IPMNs with worrisome features, more frequent follow-up every 3-6 months is recommended 7, 2

Imaging Modalities

• MRI with MRCP is the preferred imaging modality for IPMN follow-up due to superior characterization of ductal communication and internal architecture 1, 6
• CT can be used as an alternative when MRI is contraindicated or unavailable 6
• EUS should be used selectively, particularly when there are concerning features requiring tissue sampling 7, 1

Duration of Surveillance

• Surveillance should continue lifelong as long as the patient remains fit for surgery 1, 8
• The risk of IPMN progression increases over time, with malignant transformation risk of approximately 0.24% per year 6
• Even after partial pancreatectomy for IPMN, lifelong follow-up is indicated due to risk of new lesions in the remnant pancreas 1, 2

Risk Factors Requiring More Intensive Surveillance

• Presence of mural nodules (≥5 mm) 2
• Main pancreatic duct dilation ≥5 mm 2, 4
• Cyst size ≥40 mm 1, 4
• Growth rate ≥5 mm/year or total growth of 10 mm 2, 3
• Elevated serum CA 19-9 (>37 U/mL) 2, 4

Special Considerations

• For undefined cysts <15 mm with no risk factors, re-examination after 1 year is recommended; if stable for 3 years, follow-up may be extended to every 2 years 8
• For undefined cysts ≥15 mm, follow-up every 6 months during the first year and annually thereafter is recommended 8
• Organ transplant recipients with IPMN should undergo the same surveillance protocol as non-transplanted patients 8

Pitfalls to Avoid

• Do not discontinue surveillance even after years of stability, as the risk of malignant progression increases over time 1, 3
• Do not rely solely on cyst size for risk assessment; consider multiple risk factors including growth rate, mural nodules, and MPD dilation 2
• Do not use the same follow-up protocol for all types of IPMNs; tailor the approach based on IPMN subtype and risk factors 5, 1
• Do not neglect surveillance of the remnant pancreas after partial pancreatectomy for IPMN 5, 1